RCC
MCID: RNL114
MIFTS: 79

Renal Cell Carcinoma, Nonpapillary (RCC)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 57 29 6
Renal Cell Carcinoma 57 12 75 53 59 74 37 15 17 72
Adenocarcinoma of Kidney 57 12 53 74
Rcc 57 12 59 74
Hypernephroma 57 12 74
Hereditary Clear Cell Renal Cell Carcinoma 59 72
Renal Carcinoma, Chromophobe, Somatic 57 13
Nonpapillary Renal Cell Carcinoma 12 15
Clear Cell Renal Carcinoma 74 17
Renal Cell Adenocarcinoma 53 17
Carcinoma, Renal Cell 44 40
Hereditary Clear Cell Renal Cell Adenocarcinoma 59
Renal Cell Carcinoma, Clear Cell, Somatic 57
Conventional Renal Cell Carcinoma 72
Carcinoma, Renal Cell, Nonpapillary 40
Renal Cell Carcinoma Non-Papillary 74
Conventional Renal Cell Carcinoma 74
Renal Cell Carcinoma, Somatic 57
Common Renal Cell Carcinoma 74
Carcinoma Renal Cell 55
Renal Cell Cancer 15
Ccrcc 74
Crcc 74

Characteristics:

Orphanet epidemiological data:

59
renal cell carcinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

HPO:

32
renal cell carcinoma, nonpapillary:
Inheritance sporadic


Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:0050387 DOID:4450
OMIM 57 144700
KEGG 37 H00021
MeSH 44 D002292
NCIt 50 C9385
SNOMED-CT 68 41607009
MESH via Orphanet 45 D002292
ICD10 via Orphanet 34 C64
UMLS via Orphanet 73 C0007134
UMLS 72 C0007134 C0279702 C1333985

Summaries for Renal Cell Carcinoma, Nonpapillary

OMIM : 57 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700)

MalaCards based summary : Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to hereditary renal cell carcinoma and clear cell papillary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is FLCN (Folliculin), and among its related pathways/superpathways are Renal cell carcinoma and Transcriptional misregulation in cancer. The drugs Fentanyl and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and endothelial, and related phenotypes are renal cell carcinoma and Decreased sensitivity to paclitaxel

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

KEGG : 37
Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.

UniProtKB/Swiss-Prot : 74 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 75 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma, Nonpapillary

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1238)
# Related Disease Score Top Affiliating Genes
1 hereditary renal cell carcinoma 35.8 RNF139 MET FLCN FHIT
2 clear cell papillary renal cell carcinoma 34.9 VHL HNF1A
3 kidney cancer 34.9 VHL TP53 MTOR MIR200C MIR141 MET
4 clear cell renal cell carcinoma 34.8 VHL TP53 SETD2 RNF139 PTEN OGG1
5 chromophobe renal cell carcinoma 34.7 HNF1B HNF1A FLCN
6 renal cell carcinoma, papillary, 1 34.6 VHL TP53 SETD2 PTEN PIK3CA NRAS
7 melanoma 32.7 TP53 PTEN NRAS MIR200C MIR141
8 hepatocellular carcinoma 32.6 TP53 PTEN PIK3CA NRAS MTOR MIR141
9 colorectal cancer 32.6 TP53 PTEN PIK3CA OGG1 NRAS MTOR
10 ovarian cancer 32.5 TP53 PTEN PIK3CA MIR200C MIR141 HNF1B
11 lung cancer susceptibility 3 32.4 TP53 PIK3CA OGG1 NRAS MET FHIT
12 cholangiocarcinoma 32.3 TP53 PTEN PIK3CA OGG1 MTOR MIR141
13 prostate cancer 32.3 TP53 PTEN PIK3CA MTOR MIR141 MET
14 breast cancer 32.2 TP53 PTEN PIK3CA MTOR MIR200C MIR141
15 ovarian clear cell carcinoma 32.2 TP53 PTEN PIK3CA HNF1B
16 lymphoma, non-hodgkin, familial 32.2 TP53 PIK3CA NRAS ATM
17 lung cancer 32.1 TP53 PTEN PIK3CA OGG1 NRAS MIR200C
18 glioblastoma 32.1 TP53 PTEN PIK3CA NRAS MTOR MET
19 glioblastoma multiforme 32.0 TP53 PTEN PIK3CA MTOR MET
20 gastric cancer 31.8 TP53 PTEN PIK3CA MIR200C MIR141 MET
21 pancreatic neuroendocrine tumor 31.8 PIK3CA MTOR ATM
22 bladder urothelial carcinoma 31.8 TP53 PIK3CA NRAS MTOR FHIT
23 carcinosarcoma 31.8 TP53 PTEN PIK3CA
24 testicular germ cell tumor 31.7 TP53 PTEN MIR200C
25 adenoid cystic carcinoma 31.7 TP53 PTEN PIK3CA ATM
26 ovarian clear cell adenocarcinoma 31.6 PIK3CA MTOR HNF1B
27 squamous cell carcinoma, head and neck 31.6 TP53 PTEN PIK3CA MIR141 MET FHIT
28 suppression of tumorigenicity 12 31.6 TP53 PTEN PIK3CA
29 gastric adenocarcinoma 31.6 TP53 PTEN PIK3CA NRAS MET FHIT
30 endometrial cancer 31.6 TP53 PTEN PIK3CA MTOR MIR200C
31 differentiated thyroid carcinoma 31.6 TP53 NRAS MET FHIT DIRC3
32 cervical cancer 31.4 TP53 PTEN PIK3CA MTOR FHIT
33 ovary adenocarcinoma 31.4 TP53 PIK3CA HNF1B
34 ovarian serous cystadenocarcinoma 31.3 TP53 PIK3CA NRAS
35 brain cancer 31.2 TP53 PTEN PIK3CA NRAS
36 familial renal oncocytoma 31.2 MET FLCN
37 li-fraumeni syndrome 31.1 TP53 PTEN ATM
38 leukemia, chronic lymphocytic 31.1 TP53 NRAS MIR141 ATM
39 tuberous sclerosis 31.0 VHL PIK3CA MTOR
40 eosinophilic variant of chromophobe renal cell carcinoma 12.4
41 mucinous tubular and spindle renal cell carcinoma 12.4
42 multilocular clear cell renal cell carcinoma 12.4
43 obsolete: renal cell carcinoma associated with neuroblastoma 12.4
44 hereditary conventional renal cell carcinoma 12.4
45 classic variant of chromophobe renal cell carcinoma 12.2
46 obsolete: familial renal cell carcinoma 12.2
47 multilocular cystic renal neoplasm of low malignant potential 11.8
48 childhood kidney cell carcinoma 11.7
49 von hippel-lindau syndrome 11.7
50 bap1 tumor predisposition syndrome 11.6

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

32
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 32 HP:0005584

Clinical features from OMIM:

144700

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

GenomeRNAi Phenotypes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 PTEN VHL

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Nonpapillary:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 ATM FLCN HNF1A MET MTOR NRAS
2 homeostasis/metabolism MP:0005376 10.28 ATM FHIT FLCN HNF1A HNF1B MET
3 growth/size/body region MP:0005378 10.26 ATM FLCN HNF1A HNF1B MET MTOR
4 cardiovascular system MP:0005385 10.25 ATM FLCN MET MTOR NRAS PIK3CA
5 embryo MP:0005380 10.25 ATM FLCN HNF1B MET MTOR NRAS
6 immune system MP:0005387 10.25 ATM FHIT FLCN HNF1B MET MTOR
7 endocrine/exocrine gland MP:0005379 10.19 ATM HNF1A HNF1B MET MTOR NRAS
8 hematopoietic system MP:0005397 10.16 ATM FHIT FLCN MTOR NRAS OGG1
9 adipose tissue MP:0005375 10.1 ATM HNF1A MTOR PIK3CA PTEN SETD2
10 mortality/aging MP:0010768 10.1 ATM FHIT FLCN HNF1A HNF1B MET
11 digestive/alimentary MP:0005381 10.07 FHIT HNF1A MET NRAS PTEN TP53
12 integument MP:0010771 9.97 ATM FHIT HNF1A NRAS PIK3CA PTEN
13 liver/biliary system MP:0005370 9.97 HNF1A HNF1B MET NRAS OGG1 PTEN
14 muscle MP:0005369 9.76 HNF1A HNF1B MET MTOR PIK3CA PTEN
15 neoplasm MP:0002006 9.7 ATM FHIT FLCN MET NRAS OGG1
16 renal/urinary system MP:0005367 9.23 FLCN HNF1A HNF1B MET MTOR PTEN

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 501)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Caffeine Approved Phase 4 58-08-2 2519
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
9
Nicotine Approved Phase 4 54-11-5 942 89594
10
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
11
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13 Neurotransmitter Agents Phase 4
14 Anesthetics, General Phase 4
15 Autonomic Agents Phase 4
16 Platelet Aggregation Inhibitors Phase 4
17 Narcotics Phase 4
18 Adjuvants, Anesthesia Phase 4
19 Hypnotics and Sedatives Phase 4
20 Anesthetics, Intravenous Phase 4
21 Tranquilizing Agents Phase 4
22 Central Nervous System Stimulants Phase 4
23 Purinergic P1 Receptor Antagonists Phase 4
24 GABA Agents Phase 4
25 Phosphodiesterase Inhibitors Phase 4
26 GABA Modulators Phase 4
27 Psychotropic Drugs Phase 4
28 Cholinergic Agents Phase 4
29 Anesthetics, Inhalation Phase 4
30 Adrenergic alpha-2 Receptor Agonists Phase 4
31 Dopamine Agents Phase 4
32 Nicotinic Agonists Phase 4
33 Antidepressive Agents Phase 4
34 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
35 Antidepressive Agents, Second-Generation Phase 4
36 Neurotransmitter Uptake Inhibitors Phase 4
37 Dopamine Uptake Inhibitors Phase 4
38 Protein Kinase Inhibitors Phase 4
39 Liver Extracts Phase 4
40 Anesthetics, Local Phase 4
41 Anesthetics Phase 4
42 Central Nervous System Depressants Phase 4
43 Anti-Arrhythmia Agents Phase 4
44 Analgesics, Opioid Phase 4
45 Sodium Channel Blockers Phase 4
46 Diuretics, Potassium Sparing Phase 4
47 Pharmaceutical Solutions Phase 4
48 Hormones Phase 4
49 Hydroxyethyl Starch Derivatives Phase 4
50 Plasma Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 1653)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
3 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
4 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
5 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
6 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
8 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
9 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
10 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
11 A Single-Center Double Arm Single-Blinded Randomized Screening Clinical Trial to Evaluate the Use of Human Dehydrated Amnion/Chorion Membrane to Facilitate the Recovery of Renal Function Following Robotic Partial Nephrectomy Completed NCT03323021 Phase 4
12 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
13 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
14 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
15 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
16 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
17 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
18 A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy Recruiting NCT03824808 Phase 4 Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
19 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
20 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
21 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
22 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
23 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
24 Safety Study of Nivolumab for Selected Advanced Malignancies in India Active, not recruiting NCT03444766 Phase 4 Nivolumab
25 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Not yet recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
26 Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging Not yet recruiting NCT04021238 Phase 4 Perflutren lipid microsphere;Sulfur hexafluoride lipid microspheres
27 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
28 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
29 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
30 Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
31 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
32 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
33 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
34 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
35 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
36 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
37 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
38 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
39 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
40 A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma Completed NCT00586105 Phase 3 Sorafenib (Nexavar, BAY43-9006)
41 An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
42 Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC). Completed NCT00502034 Phase 3 Interferon Alfa-2a;Interleukin-2
43 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
44 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
45 A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
46 A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer. Completed NCT00073307 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
47 An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
48 Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Completed NCT00606866 Phase 3 placebo;Sorafenib;Sorafenib
49 A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma Completed NCT00002473 Phase 3
50 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Bevacizumab;Interferon-Alfa 9MU

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Medroxyprogesterone
medroxyprogesterone acetate
Nivolumab
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide

Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29 FLCN HNF1A HNF1B OGG1 RNF139 SLC49A4 VHL

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

MalaCards organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

41
Kidney, Lung, Endothelial, Bone, Brain, Thyroid, T Cells

Publications for Renal Cell Carcinoma, Nonpapillary

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 30631)
# Title Authors PMID Year
1
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 9 38 8 71
15649945 2005
2
A germline mutation in PBRM1 predisposes to renal cell carcinoma. 38 8 71
25911086 2015
3
Integrated molecular analysis of clear-cell renal cell carcinoma. 38 8
23797736 2013
4
Comprehensive molecular characterization of clear cell renal cell carcinoma. 38 8
23792563 2013
5
BAP1 loss defines a new class of renal cell carcinoma. 38 8
22683710 2012
6
Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery. 38 8
20503330 2010
7
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 38 8
20054297 2010
8
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 9 38 88
18925646 2008
9
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. 38 8
18260086 2008
10
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. 38 8
17539022 2007
11
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. 38 8
17311301 2007
12
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. 38 8
16798883 2006
13
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. 38 8
16814207 2006
14
Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. 38 8
15016767 2004
15
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. 9 8
12837690 2003
16
The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. 38 8
12694227 2003
17
Understanding familial and non-familial renal cell cancer. 38 8
12351585 2002
18
Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21). 38 8
11996788 2002
19
Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). 9 8
11284032 2001
20
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. 38 8
10807693 2000
21
The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. 38 8
10232606 1999
22
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. 38 8
9721855 1998
23
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. 38 8
9689122 1998
24
An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. 38 8
9585616 1998
25
A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. 38 8
9461085 1998
26
The Heidelberg classification of renal cell tumours. 38 8
9390023 1997
27
Renal-cell carcinoma. 38 8
8778606 1996
28
A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. 38 8
8159756 1994
29
Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. 38 8
1433648 1992
30
Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. 38 8
1348014 1992
31
Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. 38 8
1553556 1992
32
Molecular and cellular characterization of human renal cell carcinoma cell lines. 38 8
1345811 1992
33
The region of common allelic losses in sporadic renal cell carcinoma is bordered by the loci D3S2 and THRB. 38 8
1685475 1991
34
Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. 38 8
1671000 1991
35
Familial renal cell carcinoma: hereditary or coincidental? 38 8
2398557 1990
36
Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. 38 8
1969617 1990
37
A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. 38 8
2914707 1989
38
Do human renal cell carcinomas arise by a double-loss mechanism? 38 8
3203309 1988
39
Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. 38 8
3417313 1988
40
Genomic defects in nonfamilial renal cell carcinoma. Possible specific chromosome change. 38 8
3395987 1988
41
Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. 38 8
2835149 1988
42
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. 38 8
2894030 1988
43
Loss of der(3) in renal carcinoma cells of a patient with constitutional t(3;12). 38 8
3422215 1988
44
Specific chromosome aberration in human renal cell carcinoma. 38 8
3610386 1987
45
Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. 38 8
3594418 1987
46
Deletion 3p: the only chromosome loss in a primary renal cell carcinoma. 38 8
3567881 1987
47
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. 38 8
2885753 1987
48
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus. 38 8
3467112 1986
49
Rearrangement of chromosome 3 in renal cell carcinoma. 38 8
3943052 1986
50
Specific chromosome anomalies and predisposition to human breast, renal cell, and colorectal carcinoma. 38 8
3940177 1986

Variations for Renal Cell Carcinoma, Nonpapillary

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

6 (show top 50) (show all 802)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CTNNB1 NM_001904.4(CTNNB1): c.1374A> C (p.Glu458Asp) single nucleotide variant other rs1553631848 3:41275208-41275208 3:41233717-41233717
2 HNF1A NM_000545.6(HNF1A): c.814C> T (p.Arg272Cys) single nucleotide variant Pathogenic rs1555212014 12:121432067-121432067 12:120994264-120994264
3 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
4 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
5 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
6 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
7 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 3:10191555-10191555 3:10149871-10149871
8 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic rs5030818 3:10191488-10191488 3:10149804-10149804
9 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic rs5030820 3:10191506-10191506 3:10149822-10149822
10 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
11 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
12 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
13 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
14 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
15 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
16 MET NM_001127500.3(MET): c.3446T> C (p.Met1149Thr) single nucleotide variant Pathogenic rs121913668 7:116418881-116418881 7:116778827-116778827
17 MET NM_001127500.3(MET): c.3616G> T (p.Val1206Leu) single nucleotide variant Pathogenic rs121913669 7:116422081-116422081 7:116782027-116782027
18 MET NM_001127500.3(MET): c.3712G> A (p.Val1238Ile) single nucleotide variant Pathogenic rs121913670 7:116423383-116423383 7:116783329-116783329
19 MET NM_001127500.3(MET): c.3637C> G (p.Leu1213Val) single nucleotide variant Pathogenic rs121913673 7:116422102-116422102 7:116782048-116782048
20 MET NM_001127500.3(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 7:116417464-116417464 7:116777410-116777410
21 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
22 HNF1A NM_000545.6(HNF1A): c.1340C> T (p.Pro447Leu) single nucleotide variant Pathogenic rs137853236 12:121435307-121435307 12:120997504-120997504
23 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
24 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
25 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
26 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
27 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
28 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
29 MET NM_001127500.3(MET): c.3328G> A (p.Val1110Ile) single nucleotide variant Pathogenic rs786202724 7:116417457-116417457 7:116777403-116777403
30 MTOR NM_004958.4(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic rs786205165 1:11217230-11217230 1:11157173-11157173
31 FLCN NM_144997.7(FLCN): c.1429C> T (p.Arg477Ter) single nucleotide variant Pathogenic rs879255678 17:17118502-17118502 17:17215188-17215188
32 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
33 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
34 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 17:7577114-7577114 17:7673796-7673796
35 FLCN NM_144997.7(FLCN): c.779+1G> T single nucleotide variant Pathogenic/Likely pathogenic rs758175953 17:17125814-17125814 17:17222500-17222500
36 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
37 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs786202962 17:7578403-7578403 17:7675085-7675085
38 MTOR NM_004958.4(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 1:11184573-11184573 1:11124516-11124516
39 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
40 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
41 VHL NM_000551.3(VHL): c.319C> G (p.Arg107Gly) single nucleotide variant Pathogenic/Likely pathogenic rs397516440 3:10183850-10183850 3:10142166-10142166
42 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
43 MET NM_001127500.3(MET): c.3736G> A (p.Asp1246Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913671 7:116423407-116423407 7:116783353-116783353
44 MET NM_001127500.3(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 7:116423414-116423414 7:116783360-116783360
45 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
46 TP53 NM_000546.5(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Pathogenic/Likely pathogenic rs730882008 17:7577093-7577093 17:7673775-7673775
47 MTOR NM_004958.4(MTOR): c.4447T> C (p.Cys1483Arg) single nucleotide variant Pathogenic/Likely pathogenic rs1057519914 1:11217231-11217231 1:11157174-11157174
48 NRAS NM_002524.5(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
49 PIK3CA NM_006218.4(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 3:178936091-178936091 3:179218303-179218303
50 MTOR NM_004958.4(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 1:11184573-11184573 1:11124516-11124516

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

74
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

9 (show top 50) (show all 2615)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 15
2 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 15
3 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
4 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 15
5 COSM5012058 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 9:107003322-107003322 15
6 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 15
7 COSM5010682 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 15
8 COSM5013462 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 15
9 COSM5011020 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3322G>T p.D1108Y 2:218642705-218642705 15
10 COSM6934293 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 15
11 COSM6970086 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 15
12 COSM6940591 ZFHX3 kidney,NS,carcinoma,chromophobe renal cell carcinoma c.4509G>T p.Q1503H 16:72798173-72798173 15
13 COSM3276983 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 15
14 COSM5014655 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 6:151366135-151366135 15
15 COSM6961023 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 15
16 COSM6935891 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
17 COSM5012645 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1218C>A p.F406L 13:20809842-20809842 15
18 COSM6916551 XPO1 kidney,NS,carcinoma,papillary renal cell carcinoma c.259A>G p.I87V 2:61522653-61522653 15
19 COSM2888871 XKR7 kidney,NS,carcinoma,papillary renal cell carcinoma c.1409C>T p.T470M 20:31997126-31997126 15
20 COSM6946890 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 15
21 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 15
22 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 15
23 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 11:32434810-32434810 15
24 COSM6201648 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1228+1G>C p.? 11:32391971-32391971 15
25 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 23:54238942-54238942 15
26 COSM5012777 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 14:63599683-63599683 15
27 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13:41701456-41701456 15
28 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13:41865963-41865963 15
29 COSM6930635 VTCN1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.98-1G>T p.? 1:117156922-117156922 15
30 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 8:99274262-99274262 15
31 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 3:10149822-10149822 15
32 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 15
33 COSM14375 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.343C>T p.H115Y 3:10146516-10146516 15
34 COSM17715 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.221T>A p.V74D 3:10142068-10142068 15
35 COSM17807 VHL kidney,NS,carcinoma,papillary renal cell carcinoma c.264G>C p.W88C 3:10142111-10142111 15
36 COSM17855 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.233A>G p.N78S 3:10142080-10142080 15
37 COSM18024 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.598C>T p.R200W 3:10149921-10149921 15
38 COSM18074 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.193T>C p.S65P 3:10142040-10142040 15
39 COSM18152 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.463G>A p.V155M 3:10146636-10146636 15
40 COSM30224 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.326T>G p.I109S 3:10142173-10142173 15
41 COSM14318 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.231C>A p.C77* 3:10142078-10142078 15
42 COSM14373 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.400G>T p.E134* 3:10146573-10146573 15
43 COSM14389 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.452T>G p.I151S 3:10146625-10146625 15
44 COSM97151 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.477A>T p.K159N 3:10149800-10149800 15
45 COSM1417312 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.424G>A p.V142I 3:10146597-10146597 15
46 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 3:10142041-10142041 15
47 COSM17657 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.472C>G p.L158V 3:10149795-10149795 15
48 COSM17909 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.482G>C p.R161P 3:10149805-10149805 15
49 COSM18350 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 15
50 COSM14290 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.240T>A p.S80R 3:10142087-10142087 15

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

7 (show top 50) (show all 1298)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma, Nonpapillary

Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.

Pathways for Renal Cell Carcinoma, Nonpapillary

Pathways related to Renal Cell Carcinoma, Nonpapillary according to KEGG:

37
# Name Kegg Source Accession
1 Renal cell carcinoma hsa05211
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 TP53 PTEN PIK3CA NRAS MTOR ATM
2
Show member pathways
12.93 TP53 PTEN PIK3CA NRAS MTOR MET
3
Show member pathways
12.83 TP53 PTEN PIK3CA NRAS MTOR
4 12.79 VHL TP53 PTEN PIK3CA NRAS MTOR
5
Show member pathways
12.74 TP53 PTEN PIK3CA NRAS MTOR MET
6
Show member pathways
12.68 TP53 PTEN PIK3CA NRAS MTOR MET
7
Show member pathways
12.67 TP53 PTEN PIK3CA NRAS MTOR MET
8
Show member pathways
12.45 PTEN PIK3CA NRAS MTOR
9
Show member pathways
12.45 TP53 PTEN PIK3CA NRAS MTOR MET
10
Show member pathways
12.43 PIK3CA NRAS MTOR MET
11
Show member pathways
12.39 TP53 PIK3CA NRAS MTOR MET ATM
12
Show member pathways
12.37 TP53 PTEN PIK3CA MTOR MET
13 12.33 TP53 PIK3CA NRAS ATM
14
Show member pathways
12.33 TP53 PTEN PIK3CA NRAS MTOR MET
15
Show member pathways
12.29 PTEN PIK3CA NRAS MTOR
16
Show member pathways
12.25 VHL TP53 PIK3CA NRAS MTOR MET
17 12.24 TP53 PIK3CA NRAS MTOR MET
18
Show member pathways
12.17 TP53 PTEN PIK3CA NRAS MTOR MET
19
Show member pathways
12.16 TP53 PIK3CA NRAS MTOR
20 12.14 TP53 PTEN MTOR ATM
21
Show member pathways
12.12 TP53 PIK3CA NRAS MTOR
22 12.09 TP53 PTEN PIK3CA NRAS MTOR ATM
23
Show member pathways
12.07 PTEN PIK3CA NRAS ATM
24 12.07 PTEN PIK3CA NRAS MTOR
25 12.07 TP53 PTEN PIK3CA NRAS MTOR MET
26
Show member pathways
12.04 TP53 NRAS MTOR ATM
27 12 TP53 PTEN PIK3CA NRAS
28 11.99 TP53 PIK3CA NRAS MTOR
29 11.95 TP53 PTEN NRAS MTOR
30 11.94 TP53 PTEN PIK3CA NRAS ATM
31 11.91 VHL PIK3CA MTOR
32
Show member pathways
11.87 PIK3CA MTOR HNF1B HNF1A
33 11.84 TP53 PTEN PIK3CA FHIT
34 11.79 TP53 PTEN MTOR
35 11.77 TP53 PTEN PIK3CA NRAS MTOR MIR200C
36 11.72 RNF139 PIK3CA MTOR
37
Show member pathways
11.72 TP53 MTOR ATM
38 11.71 TP53 PIK3CA ATM
39 11.59 TP53 SETD2 PTEN PIK3CA ATM
40 11.57 TP53 PTEN PIK3CA
41 11.49 TP53 PTEN ATM
42 11.28 TP53 NRAS ATM
43 11.27 TP53 PTEN PIK3CA NRAS MTOR MET
44 11.26 NRAS MTOR MET
45 11.23 PTEN PIK3CA NRAS MTOR
46 10.87 VHL TP53

GO Terms for Renal Cell Carcinoma, Nonpapillary

Cellular components related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TP53 PTEN MTOR

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.65 TP53 PTEN MTOR HNF1B ATM
2 negative regulation of apoptotic process GO:0043066 9.55 VHL TP53 PTEN OGG1 HNF1B
3 response to glucose GO:0009749 9.54 PTEN HNF1B HNF1A
4 negative regulation of macroautophagy GO:0016242 9.48 PIK3CA MTOR
5 replicative senescence GO:0090399 9.46 TP53 ATM
6 anoikis GO:0043276 9.43 PIK3CA MTOR
7 negative regulation of cell size GO:0045792 9.4 PTEN MTOR
8 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 9.32 HNF1B HNF1A
9 regulation of pronephros size GO:0035565 8.96 HNF1B HNF1A
10 liver development GO:0001889 8.92 PIK3CA MET HNF1B HNF1A

Molecular functions related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.35 NRAS MTOR MET FHIT ATM
2 protein-containing complex binding GO:0044877 9.02 NRAS MTOR HNF1B FLCN ATM

Sources for Renal Cell Carcinoma, Nonpapillary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....